Vol 2, No 1 (2011)
Case report
Published online: 2011-03-24

open access

Page views 615
Article views/downloads 5655
Get Citation

Connect on Social Media

Connect on Social Media

Efficacy of rituximab in refractory primary immune thrombocytopenia

Agnieszka Kopacz
Hematologia 2011;2(1):88-91.

Abstract

This paper presents the case report of efficient use of rituximab in the treatment of refractory primary immune thrombocytopenia (ITP). Despite initial response to corticosteroids, most adults relapse during corticosteroid taper. Splenectomy should be taken into consideration in such situations. Those whom splenectomy fails to cure present a therapeutic challenge. Subsequent management usually involves some form of chronic immune suppression which, however, has serious side effects. The case of patient with refractory ITP, who achieved increased platelet counts and then the remission of disease after treatment with rituximab, is discussed in this paper.
Hematologia 2011; 2, 1: 88–91

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice